Every 8-K that Champions Oncology, Inc. (CSBR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CSBR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CSBR filings page.
Champions Oncology, Inc. (CSBR) reported the results of its October 14, 2026 annual meeting. Stockholders elected all seven director nominees—Robert Brainin, Ronnie Morris, M.D., Joel Ackerman, David Sidransky, M.D., Daniel Mendelson, Scott R. Tobin and Brian Alexander, M.D.—to one-year terms expiring at the 2027 Annual Meeting of Stockholders. They ratified EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2027, approved the non-binding executive-compensation resolution and the 2026 Equity Incentive Plan, and recommended annual advisory votes on executive compensation. The company intends to hold those votes every year.
Champions Oncology, Inc. (CSBR) reported first-quarter fiscal 2027 oncology revenue of $15.2 million, up 8.8% from $14.0 million a year earlier, driven by higher core research services and increased data license revenue. Oncology services margin improved to 51% from 43%, reflecting higher revenue and lower third-party radiolabeling costs.
The company recorded a net loss of $426,000, slightly better than the $466,000 loss in the prior-year period, and generated Adjusted EBITDA of $671,000, up from $59,000, as higher gross profit offset increased investment in R&D and commercial expansion. Operating expenses rose 7.7% to $15.6 million, including higher sales and marketing and stock-based compensation.
Net cash used in operating activities was $492,000 versus $600,000 provided in the prior-year quarter. Champions ended the quarter with $4.4 million in cash and no debt, total assets of $33.3 million, and deferred revenue of $9.6 million, indicating a solid backlog of contracted work despite ongoing net losses.
Champions Oncology reported record fiscal 2026 oncology revenue of $59.4 million, up 4% from $56.9 million, driven by its core research services business despite the absence of approximately $4.5 million of prior-year data license revenue. Fourth-quarter revenue rose 12% to $13.8 million, and oncology services margin improved to 51% from 41% as costs of oncology revenue fell 6%.
Profitability weakened for the year. Champions posted a loss from operations of $1.1 million, versus income from operations of $4.6 million in fiscal 2025, and a GAAP net loss of $1.2 million versus prior-year net income of $4.7 million, reflecting higher outsourced radiopharmaceutical costs and increased R&D, sales and marketing, and G&A expenses. Adjusted EBITDA remained positive at $1.6 million, but declined from $7.1 million; in the fourth quarter, Adjusted EBITDA was $158,000 compared with a $1.2 million loss a year earlier.
Operating cash use in the fourth quarter was approximately $2.2 million, mainly from working-capital timing and lower deferred revenue. Champions ended April 30, 2026 with $4.9 million in cash and no debt while continuing to invest in radiopharmaceuticals, its data platform, and commercial organization.
Champions Oncology, Inc. reported that its Board of Directors accepted the resignation of Dr. Philip Breitfeld and appointed Dr. Brian Alexander as a director to fill the vacancy. The company stated that Dr. Breitfeld’s resignation was not due to any disagreement over operations, policies, or practices.
The company noted there is no arrangement or understanding with other persons regarding Dr. Alexander’s appointment, no related-party transactions requiring disclosure, and no material plans or contracts tied to his appointment. Dr. Alexander is an experienced oncology and data-science leader, currently serving as CEO of Valo Health and CEO-Partner at Flagship Pioneering.
Champions Oncology highlighted that his background in oncology, artificial intelligence, and data-driven drug development supports its strategy of linking patient-derived tumor models with molecular and clinical datasets to power a more data-informed translational research platform.
Champions Oncology reported third quarter fiscal 2026 oncology revenue of $16.6 million, slightly below the prior year’s $17.0 million as a large $4.5 million data license from last year did not repeat. Study service revenue still grew about 32%, reflecting strong project execution.
The company posted a GAAP net loss of $279,000 versus net income of $4.5 million a year earlier, while adjusted EBITDA fell to $574,000 from $5.1 million as oncology services margin declined to 47% from 61% due to higher outsourced lab costs and mix shift.
For the nine months ended January 31, 2026, revenue edged up to $45.6 million from $44.6 million, but results swung to a net loss of $508,000 from $6.5 million of net income, with adjusted EBITDA decreasing to $1.5 million from $8.3 million. Champions ended the quarter with $7.1 million in cash and no debt, while increasing investment in R&D, sales and marketing, and its data platform to support future growth.
Champions Oncology, Inc. filed a current report to disclose that on December 15, 2025 it issued a press release announcing its unaudited financial results for its second quarter ended October 31, 2025.
The press release is attached as Exhibit 99.1, and the company states that the financial information described under Item 2.02 is being furnished rather than filed, and will only be incorporated into other securities filings if specifically referenced.
Champions Oncology (CSBR) reported results from its October 16, 2025 Annual Meeting. All seven director nominees were elected for one-year terms. The strongest director support was for Scott R. Tobin with 9,722,734 votes for.
Stockholders ratified the appointment of EisnerAmper LLP as independent auditor with 10,659,115 votes for. The non-binding advisory vote on executive compensation was approved with 9,720,681 votes for. Broker non-votes totaled 931,779 for proposals requiring them.
Champions Oncology, Inc. filed a current report to note that it issued a press release covering its unaudited financial results for the first quarter ended July 31, 2025. The press release is provided as Exhibit 99.1 to the report so investors can review the detailed quarterly information.
The company states that the information under this earnings item is being furnished, not filed, under securities law, which affects how it is treated for certain legal purposes and future SEC filings.